SYN1002
A New Therapeutic Option to Protect Central Nervous System against Acute Ischemic Stroke
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0SYN1002 project word cloud
Explore the words cloud of the SYN1002 project. It provides you a very rough idea of what is the project "SYN1002" about.
Project "SYN1002" data sheet
The following table provides information about the project.
| Coordinator |
ORPHIT
Organization address contact info |
| Coordinator Country | France [FR] |
| Project website | http://www.orphitpharma.com |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) |
| Code Call | H2020-SMEINST-1-2016-2017 |
| Funding Scheme | SME-1 |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-08-01 to 2018-01-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | ORPHIT | FR (SAINT-LAURENT-DU-VAR) | coordinator | 50˙000.00 |
Map
Project objective
Each year, about 16 million strokes occur in the world causing millions of deaths and one third of patients experiencing permanent disability. The main treatment of stroke is thrombolytic agent recombinant tissue plasminogen activator (rtPA). Not all the patient can qualify for this treatment and it can be administered only in a limited time window. No existing drug is approved to protect against ongoing neuronal damage after the acute event. In this framework, our company, ORPHIT, a seed-stage biotech company, intends to be a pioneer by bringing clinical proof of concept of our peptide SYN1002 as suitable neuroprotective anti-inflammatory agent to treat stoke in acute phase that could be administered at multiple doses as complement to current thrombolytic treatments and also in patients who do not qualify for treatment with rtPA. This peptide is our lead product and has been initially developed as a potent anti-inflammatory substance in auto-immune pathologies with a clinical phase 1 study successfully documenting the safety and tolerability. Its properties make it a perfect match with current needs on Stroke treatment. Therefore, our solution is of interest for the pharmaceutical industry and health institutes who are currently in the search of a treatment that would be efficient and safe enough to be applicable to a larger part of the persons suffering from Stroke. The acute ischemic stroke (AIS) therapeutic market generated 400M€ in 2012 across the six major markets and is expected to reach 1.1 billion € by the end of 2017. SYN1002 sales at peak (2026) are expected to achieve 50% of market share, and a licensing deal at end of phase IIa would come out with a net present value of 265M€ for our company. In order to achieve this goal ORPHIT will realize a feasibility study aiming at strengthening SYN1002 preclinical package in AIS indication, confirming drug positioning through in depth market study, and draw a European business plan.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SYN1002" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SYN1002" are provided by the European Opendata Portal: CORDIS opendata.
